ORGANISATION

Workshop Fee

400 € Non-Member

300 € Member of AGAH | EUFEMED and DGKliPha or young scientistics until the age of 30 years

100 € Member of Regulatory Agencies and ethics commission

Delegate number is limited to 70 persons.

Final Registration: November 1, 2019

VENUE

GSI - Gustav Stresemann Institut Bonn
Langer Grabenweg 68
53175 Bonn
Web: www.gsi-bonn.de

REGISTRATION

CSi Hamburg GmbH
Goernestraße 30
20249 Hamburg
phone: +49 40 30770300
fax: +49 40 30770301
e-Mail: agah-meetings@csihamburg.de

Download_Registrationform (engl.) PDF

Download Anmeldeformblatt PDF

CONTACT

Arbeitsgemeinschaft für angewandte Humanpharmakologie (AGAH) e. V.
Office
Goernestraße 30 · 20249 Hamburg
phone: +49 (0)40 30772097
e-Mail: info@agah.eu
web: www.agah.eu

FACULTY

Dr. Kerstin Breithaupt-Grögler
-kbr- clinical pharmacology services, Frankfurt/Main

Dr. Frank Donath
SocraTec R&D GmbH, Erfurt

Dr. Katharina Erb-Zohar
clinphase®, Schotten

Dr. Klaus Francke
Bayer AG, Berlin

Prof. Dr. Joop van Gerven
CHDR, Leiden/NL

Prof. Dr. Jörg Hasford
Arbeitskreis medizinischer Ethik-Kommissionen, Munich

Dr. Sarah Heil
Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn

Dr. Dagmar Kubitza
Bayer AG, Wuppertal

Prof. Dr. Gerd Mikus
Clinical Pharmacology and Pharmacoepidemiology, University Hospital, Heidelberg

Dr. Stephanie Plassmann
PreClinical Safety Consultants, Basel/CH

Dr. Jens Rengelshausen
Grünenthal GmbH, Aachen

Dr. Claudia Riedel
Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn

Prof. Dr. Hildegard Sourgens
Consultant, Munich

Dr. Elke Stahl
Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn

PD Dr. Thomas Sudhop
Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn

Dr. Lutz Wiesner
Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn

Prof. Dr. Georg Wensing
Bayer AG, Wuppertal

AGAH
Arbeitsgemeinschaft für angewandte Humanpharmakologie e.V.
Association for Applied Human Pharmacology

AGAH DISCUSSION FORUM



HOW TO INTERPRETE AN INVESTIGATOR'S BROCHURE FOR MEANINGFUL RISK ASSESSMENT

NOVEMBER 11, 2019
BONN

CONTENT

The Investigator's Brochure is the key document for the Sponsor to compile the pertinent knowledge on the pharmaceutical, pharmacological, and toxicological characteristics of and –if any- the clinical experience with the investigational medicinal product (IMP). Critical appraisal of potential safety risks and appropriate precautions on how to avoid putting healthy subjects or patients receiving the IMP at risk is required to provide guidance for the investigator.

In first-in-human and early phase clinical trials, clinical experience with the IMP is lacking or sparse and non-clinical safety assessments must enable an adequate risk assessment to support the transition from animal models to man.

This AGAH discussion forum will debate what is required from an IB to provide proper guidance for the investigator about an IMP in early clinical trials.

The discussion forum addresses investigators and trial teams with some hands-on experience in early phase clinical trials. Clinicians performing first in human trials / early clinical trials in patients may equally profit from this workshop.



Hildegard Sourgens
Past President EUFEMED*

Kerstin Breithaupt-Grögler
Consultant to the AGAH Board

AGAH e. V. is a founding member of the European Federation for Early Medicines Development, Brussels

MORNING SESSION

08:00 Registration

09:00 Welcome and Moderation
K. Breithaupt, Frankfurt/M.
H. Sourgens, München

Online Survey (Who attends this workshop?)

09:15 **The Investigator's Brochure - Key information to support early clinical trials**
J. van Gerven, Leiden/NL

10:00 **Deficiencies / Uncertainties in IBs - The Regulatory Authority's experience**
E. Stahl, Bonn; T. Sudhop, Bonn

Online Survey (Experience of the audience: Quality of the IB regarding Sections 1 to 6)
K. Erb-Zohar, Schotten; J. Rengelshausen, Aachen

11:00 Break

11:30 **Guidance for the Investigator**
Chair: *G. Mikus, Heidelberg*

View point of Sponsor; Expectations from Regulatory Agency, Ethics Committee, and Investigator
F. Donath, Erfurt
J. Hasford, München
K. Francke, Berlin
T. Sudhop, Bonn
G. *Wensing, Wuppertal*

Online Survey (Experience of the audience: Quality of the IB regarding Section 7)
K. Erb-Zohar, Schotten; J. Rengelshausen, Aachen

12:30 **Questions raised by the Audience - Open-Forum Discussion**
F. Donath, Erfurt
J. Hasford, Munich
S. Heil, Bonn
G. Mikus, Heidelberg
C. Riedel, Bonn
T. Sudhop, Bonn
G. Wensing, Wuppertal

AFTERNOON SESSION

13:00 Break

13:45 **Reference safety information – a key element of the IB**
K. Erb-Zohar, Schotten

Online Survey (Experience of the audience: Reference safety information in the IB)
K. Erb-Zohar, Schotten; J. Rengelshausen, Aachen

14:15 **Discussion**
F. Donath, Erfurt
K. Erb-Zohar, Schotten
D. Kubitza, Wuppertal
G. Mikus, Heidelberg
E. Stahl, Bonn

14:30 **Potential risks for human subjects associated with inadequate non-clinical safety assessment**
S. Plassmann, Basel/CH; L. Wiesner, Bonn

15:00 Break

15:15 Case study presented by *J. van Gerven, Leiden*:
Integrating data from the IB – a new tool for translational integration of preclinical effects

Online Survey (Experience of the audience: Room for improvement in the IB)
K. Erb-Zohar, Schotten; J. Rengelshausen, Aachen

16:30 **Discussion**
S. Plassmann, Basel/CH
J. van Gerven, Leiden/NL
L. Wiesner, Bonn

16:50 **Wrap-up**

17:00 End of Workshop



September 2019, modifications subject to change